About Altratech
Next Generation Molecular Detection
At Altratech, we are moving the monitoring of viral contagious diseases to the point-of-care and outside of the clinical setting, to the point of care, to the home, enabling testing by anyone, anywhere, anytime.
We are a team of twenty scientists engineers, including nine PhDs, has for the past seven years been researching and developing a Bioorthogonal alternative to PCR. With minimal sample preparation, the Altratech product and assay can rapidly detect and quantify molecular targets from any sample. The technology brings together nanotechnology, semiconductor technology and novel PNA chemistry to produce a unique and powerful assay. The assay named Molecular Detection by Proxy is a bead-based technology coupled with ultra-sensitive capacitance detection.
Altratech is creating an infrastructure of technology and data to manage contagious viral diseases, important for the future of decentralised connected healthcare and wellbeing.
This will facilitate continuous health monitoring, outside a clinical setting, at point-of-care, and in the home.
Our Unique Value Proposition:
PNA’s are synthetic, stable, and robust, with a long shelf life, so no cold-chain shipping or refrigeration is needed. They target the RNA virus directly in-situ, so no sample-prep or extraction is required. This enables operation of the Altratech platform anywhere, by anyone, in any environment, warm or cold, from home-users routinely monitoring their health or viral condition, to world-health bodies monitoring viral health statistics and infectious disease crises and pandemics in real time.
The ‘Altra-PNA-designer’ software tool is an important part of propagating emerging PNA’s to much wider use, not just by Altratech, but by researchers, scientists, clinicians, and industry generally. It is the first to automate the design of PNA probes, by searching GenBank for all genomic data on an organism of interest, ensuring maximum viral strain coverage by the final curated set of designed probes.
